Dr. David G. Hicks
Director, IHC/ISH Laboratory & Chief of the Breast Subspecialty Service - University of Rochester Medical Center
Steven A. Noel, PhD (DABCC), MT (ASCP)
Vice President of Lab Operations
Drugscan, Inc., Warminster, PA
Evolution of HER2 biomarker in Breast Cancer Diagnostics – From Identification to Monitoring
10/22/2022
HER2 over-expression/gene amplification is present in 15-20% of breast cancer and is recognized as an important prognostic and predictive biomarker associated with a more aggressive clinical course of disease.